218

SALVAGE ROBOTIC ESOPHAGECTOMY: TIPS AND TRICKS

Date
May 18, 2024

Salvage esophagectomy after definitive chemoradiotherapy treatment has traditionally been recognized as a feasible option. Robotic esophagectomy has been considered as alternative to minimize post operative complications. The thoracic field was performed robotically. This VIDEO demonstraded middle-third squamous cell carcinoma (cT3N2) after definitive treatment with 5040Gy+5-FU + paclitaxel. We particularly show the relationship to left broncqueal side and the effects of scars in mediastinum after the high dose of radiotherapy. We illustrated surgical aspect, mediastinal dissection, lysis of the intense adhesion, description of the anatomical aspects and surgical strategy.

Tracks

Related Products

Thumbnail for OUTCOMES OF GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAS TREATED WITH PERIOPERATIVE CHEMOTHERAPY WITH OR WITHOUT PREOPERATIVE RADIOTHERAPY
OUTCOMES OF GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAS TREATED WITH PERIOPERATIVE CHEMOTHERAPY WITH OR WITHOUT PREOPERATIVE RADIOTHERAPY
BACKGROUND: The standard approach for the treatment of patients with locally advanced adenocarcinomas of the gastroesophageal junction (AGEJ) includes perioperative chemotherapy (CMT) or chemoradiation therapy (CRT)…
Thumbnail for SURVIVAL DIFFERENCES FOR PATIENTS WITH GASTRIC CANCER IN THE US AND BRAZIL: A CROSS-SECTIONAL ANALYSIS OF TWO NATIONAL DATASETS
SURVIVAL DIFFERENCES FOR PATIENTS WITH GASTRIC CANCER IN THE US AND BRAZIL: A CROSS-SECTIONAL ANALYSIS OF TWO NATIONAL DATASETS
Gastric Cancer (GC) is the 4th most common cancer worldwide. Our prior analysis has shown geographic differences in mortality outcomes…
Thumbnail for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA MAY BE BIOLOGICALLY CLASSIFIED BY IMMUNOEXPRESSION OF MOLECULAR MARKERS
ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA MAY BE BIOLOGICALLY CLASSIFIED BY IMMUNOEXPRESSION OF MOLECULAR MARKERS
BACKGROUND: Despite the advances in the multidisciplinary treatment of gastric adenocarcinoma, the overall 5-year survival remains only 33.3% in North America. R0 resection with adequate lymphadenectomy remains the mainstay therapy…